Evaluation of PD-L1 expression level in non-small cell lung cancer patients by 18F-FDG PET/CT radiomics and clinicopathological characteristics

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100051551

Enrollment

Unknown

Registered

2021-09-26

Start date

2021-10-01

Completion date

Unknown

Last updated

2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Gold Standard:hematological test

Index test:18F-FDG PET/CT

Eligibility

Sex/Gender

All

Age

27 Years to 82 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing lung tumor biopsy or surgery; 2. IHC inspection of PD-L1; 3. Available pathologically confirmed histological types and grades; 4. 18F-FDG PET/CT examination before biopsy or surgery.

Exclusion criteria

Exclusion criteria: 1. Treatment (radiotherapy, chemotherapy, or chemoradiotherapy) prior to 18F-FDG PET/CT and IHC; 2. The size of the primary lesion is too small to be segmented; 3. Patients with other types of cancer or with incomplete clinical and imaging datasets.

Design outcomes

Primary

Measure	Time frame
Texture parameter;	—

Countries

China

Contacts

Public ContactDeng Shengming

The First Affiliated Hospital of Soochow University

dshming@163.com+86 15051510189

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026